Fore Pharmas latest report ‘Global Sickle Cell Anaemia Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global sickle cell anaemia drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the sickle cell anaemia drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Sickle Cell Anaemia: Overview
- Sickle Cell Anaemia Drug Pipeline Overview
- Sickle Cell Anaemia Phase 3 Clinical Trial Drug Pipeline Insights
- Sickle Cell Anaemia Phase 2 Clinical Trial Drug Pipeline Insights
- Sickle Cell Anaemia Phase 1 Clinical Trial Drug Pipeline Insights
- Sickle Cell Anaemia Preclinical Research Drug Pipeline Insights
- Sickle Cell Anaemia Drug Discovery Pipeline Insights
- Geographic Landscape of Sickle Cell Anaemia R&D Activities
- Sickle Cell Anaemia R&D Activities in North America
- Sickle Cell Anaemia R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Sickle Cell Anaemia Drug Market
 

1. Sickle Cell Anaemia: Disease Definition
2. Sickle Cell Anaemia Drug Pipeline Overview
3. Sickle Cell Anaemia Phase 3 Clinical Trial Drug Pipeline Insights
4. Sickle Cell Anaemia Phase 2 Clinical Trial Drug Pipeline Insights
5. Sickle Cell Anaemia Phase 1 Clinical Trial Drug Pipeline Insights
6. Sickle Cell Anaemia Preclinical Research Drug Pipeline Insights
7. Sickle Cell Anaemia Drug Discovery Pipeline Insights
8. Geographic Landscape of Sickle Cell Anaemia R&D Activities
8.1 Sickle Cell Anaemia R&D Activities in North America
8.2 Sickle Cell Anaemia R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Sickle Cell Anaemia Drug Market
10 Research Methodology Table 1: Sickle Cell Anaemia Drug Pipeline: Phase 3 Clinical Trial

Table 2: Sickle Cell Anaemia Drug Pipeline: Phase 2 Clinical Trial
Table 3: Sickle Cell Anaemia Drug Pipeline: Phase 1 Molecules
Table 4: Sickle Cell Anaemia Drug Pipeline: Preclinical Research
Table 5: Sickle Cell Anaemia R&D Activities by Geography
Table 6: Sickle Cell Anaemia Drug Pipeline: North America
Table 7: Sickle Cell Anaemia Drug Pipeline: Europe
Table 8: Sickle Cell Anaemia Drug Pipeline: Licensing Activities

 Figure 1 : Sickle Cell Anaemia Drug Pipeline Molecules by Stages
Figure 2 : Sickle Cell Anaemia R&D Activities by Geography